EHA 2017 | The future for CAR T-cells in treating AML

Attilio Bondanza

Attilio Bondanza, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about a Phase I/II trial, which will take place in the future, investigating the effectiveness of using CAR T-cells to treat refractory acute myeloid leukemia, sponsored by the biotechnology company, MolMed. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

Share this video  
Similar topics